Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 51 to 100 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
51\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIMKAIN B1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0656049\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.159562\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411156165\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIAA0430\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
52\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KININOGEN PRECURSOR (ALPHA-2-THIOL PROTEINASE INHIBITOR) [CONTAINS: BRADYKININ]. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.586469\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.42639\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411156135\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KNG1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
53\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DISKS LARGE-ASSOCIATED PROTEIN 2 (DAP-2) (SAP90/PSD-95-ASSOCIATED PROTEIN 2) (SAPAP2) (PSD-95/SAP90 BINDING PROTEIN 2) (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.318849\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.775495\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411155456\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
54\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PUTATIVE ADENOSYLHOMOCYSTEINASE 2 (EC 3.3.1.1) (S-ADENOSYL-L- HOMOCYSTEINE HYDROLASE) (ADOHCYASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.25896\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.629835\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411155303\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AHCYL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
55\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.231369\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.562729\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411155281\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
56\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DISKS LARGE-ASSOCIATED PROTEIN 1 (DAP-1) (GUANYLATE KINASE-ASSOCIATED PROTEIN) (HGKAP) (SAP90/PSD-95-ASSOCIATED PROTEIN 1) (SAPAP1) (PSD- 95/SAP90 BINDING PROTEIN 1). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.378587\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.920789\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.411154999\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
DLGAP1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
57\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DISKS LARGE-ASSOCIATED PROTEIN 4 (DAP-4) (SAP90/PSD-95-ASSOCIATED PROTEIN 4) (SAPAP4) (PSD-95/SAP90 BINDING PROTEIN 4). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
DLGAP4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
58\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"DJ681N20.2 (NOVEL PROTEIN SIMILAR TO FERRITIN, LIGHT POLYPEPTIDE (FTL)). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0511645\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.124441\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411154684\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
59\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DISKS LARGE-ASSOCIATED PROTEIN 3 (DAP-3) (SAP90/PSD-95-ASSOCIATED PROTEIN 3) (SAPAP3) (PSD-95/SAP90 BINDING PROTEIN 3) (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.28264\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.68743\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.41115459\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DLGAP3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
60\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CELLULAR REPRESSOR OF E1A-STIMULATED GENES. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.312681\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.760495\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.411154577\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
CREG1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
61\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PUTATIVE ADENOSYLHOMOCYSTEINASE 3 (EC 3.3.1.1) (S-ADENOSYL-L- HOMOCYSTEINE HYDROLASE) (ADOHCYASE). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
62\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CELLULAR REPRESSOR OF E1A-STIMULATED GENES 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.237385\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.577362\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411154527\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CREG2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
63\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOCHONDRIAL FERRITIN; FERRITIN HEAVY CHAIN-LIKE; FERRITIN H SUBUNIT. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.685868\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.66819\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.411145013\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FTMT\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
64\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FERRITIN HEAVY POLYPEPTIDE-LIKE 17. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.605547\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.4734\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.410986154\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FTHL17\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
65\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA POLYMERASE EPSILON P17 SUBUNIT (DNA POLYMERASE EPSILON SUBUNIT 3) (CHROMATIN ACCESSIBILITY COMPLEX 17) (HUCHRAC17) (CHRAC-17). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.446035\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.09489\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.407378823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
POLE3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
66\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNAPSIN I (BRAIN PROTEIN 4.1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.132875\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.327175\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406128219\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SYN1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
67\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PEROXISOMAL TARGETING SIGNAL 1 RECEPTOR (PEROXISMORE RECEPTOR 1) (PEROXISOMAL C-TERMINAL TARGETING SIGNAL IMPORT RECEPTOR) (PTS1-BP) (PEROXIN-5) (PTS1 RECEPTOR). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.42729\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.51439\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406127379\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PEX5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
68\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAIRY/ENHANCER-OF-SPLIT RELATED WITH YRPW MOTIF 1 (HAIRY AND ENHANCER OF SPLIT RELATED-1) (HESR-1) (CARDIOVASCULAR HELIX-LOOP-HELIX FACTOR 2) (HES-RELATED REPRESSOR PROTEIN 2 HERP2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0646859\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.159275\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406127139\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HEY1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
69\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNAPSIN II. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.159227\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.392062\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406127092\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SYN2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
70\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAIRY/ENHANCER-OF-SPLIT RELATED WITH YRPW MOTIF-LIKE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0617004\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.151924\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126748\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HEYL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
71\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACTIN BINDING LIM PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0620387\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.152757\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126724\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABLIM2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
72\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"DELTA3,5-DELTA2,4-DIENOYL-COA ISOMERASE, MITOCHONDRIAL PRECURSOR (EC 5.3.3.-). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.31296\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.770597\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126678\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ECH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
73\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR HES-1 (HAIRY AND ENHANCER OF SPLIT 1) (HAIRY- LIKE) (HHL) (HAIRY HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.285613\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.703261\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126602\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HES1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
74\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAIRY/ENHANCER-OF-SPLIT RELATED WITH YRPW MOTIF 2; GRIDLOCK; HES-RELATED REPRESSOR PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0796134\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.196031\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126582\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HEY2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
75\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOCHONDRIAL RIBOSOME RECYCLING FACTOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.291345\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.717375\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126503\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MRRF\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
76\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.212647\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.523598\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406126456\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C22orf9\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
77\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0637106\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.156874\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406125935\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABLIM3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
78\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ASPARTATE BETA-HYDROXYLASE ISOFORM B; JUNCTIN ISOFORM 1; JUNCTATE; ASPARTYL/ASPARAGINYL-BETA-HYDROXYLASE; PEPTIDE-ASPARTATE BETA-DIOXYGENASE; HUMBUG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.06383\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.157168\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406125929\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
79\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SYNAPSIN III. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.133193\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.32796\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406125747\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SYN3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
80\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACTIN-BINDING LIM PROTEIN 1 ISOFORM A; LIM ACTIN-BINDING PROTEIN 1; LIMATIN; ACTIN-BINDING LIM PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0763094\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.187896\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.406125729\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ABLIM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
81\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR DP-2 (E2F DIMERIZATION PARTNER 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.745698\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.87445\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.397822295\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TFDP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
82\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR E2F1 (E2F-1) (RETINOBLASTOMA BINDING PROTEIN 3) (RBBP-3) (PRB-BINDING PROTEIN E2F-1) (PBR3) (RETINOBLASTOMA-ASSOCIATED PROTEIN 1) (RBAP-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.198685\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.505165\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.393307137\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
E2F1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
83\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR E2F2 (E2F-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.204365\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.519607\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.393306865\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
E2F2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
84\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EUKARYOTIC TRANSLATION INITIATION FACTOR 5 (EIF-5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.375556\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.956345\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.392699287\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
85\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTION FACTOR DP-1 (E2F DIMERIZATION PARTNER 1) (DRTF1- POLYPEPTIDE-1) (DRTF1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.788778\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.02915\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.388723357\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
86\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RGS19-INTERACTING PROTEIN 1 (GAIP C-TERMINUS INTERACTING PROTEIN GIPC) (RGS-GAIP INTERACTING PROTEIN) (TAX INTERACTION PROTEIN 2) (TIP-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.20591\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.1266\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.385693725\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GIPC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
87\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.113929\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.295729\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.38524798\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PLEKHG6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
88\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APICAL-LIKE PROTEIN (APXL PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.117195\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.30421\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.385243746\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SHROOM2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
89\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.152828\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.396725\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.385224022\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
90\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHROOM-RELATED PROTEIN; F-ACTIN-BINDING PROTEIN; LIKELY ORTHOLOG OF MOUSE SHROOM. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SHROOM3\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
91\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SHROOM4\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
92\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.914796\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.37847\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.38461532\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
93\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SIGNAL TRANSDUCTION PROTEIN CBL-B (SH3-BINDING PROTEIN CBL-B). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.502064\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.32571\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.378713293\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CBLB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
94\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CBL E3 UBIQUITIN PROTEIN LIGASE (EC 6.3.2.-) (SIGNAL TRANSDUCTION PROTEIN CBL) (PROTO-ONCOGENE C-CBL). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.394562\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.04353\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.378103169\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CBL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
95\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY A MEMBER 2 (POTASSIUM CHANNEL KV1.2) (RBK2) (HBK5) (NGK1) (MK2) (HUKIV). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.22158\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.589242\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.376042441\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCNA2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
96\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY A MEMBER 1 (POTASSIUM CHANNEL KV1.1) (HUKI) (HBK1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.185899\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.494524\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.375915021\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCNA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
97\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
POTASSIUM VOLTAGE-GATED CHANNEL SUBFAMILY A MEMBER 4 (POTASSIUM CHANNEL KV1.4) (HK1) (HPCN2) (HBK4) (HUKII). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.166283\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.442453\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.375820709\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KCNA4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
98\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAV PROTO-ONCOGENE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.379284\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.01082\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.375224076\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
VAV1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
99\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAV-3 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.380273\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.015\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.374653202\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
VAV3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
100\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"INOSITOL POLYPHOSPHATE-4-PHOSPHATASE, TYPE 1 ISOFORM B; INOSITOL POLYPHOSPHATE-4-PHOSPHATASE, TYPE I, 107KD; 4-PHOSPHATASE I; INOSITOL POLYPHOSPHATE-4-PHOSPHATASE I. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0619579\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.165754\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.373794298\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
INPP4A\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/